Solubility: Soluble in DMSO (slightly), methanol (slightly, with heating)
pKa: 12.05±0.43 (predicted)
Biological Activity and Pharmacological Effects
Mechanism of Action: Dacomitinib is a specific, irreversible inhibitor of the ERBB family kinases, with IC50 values of 6 nM, 45.7 nM, and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively. It inhibits both wild-type EGFR and EGFR mutants (such as T790M) and demonstrates activity in NSCLC cell lines that are sensitive and resistant to gefitinib.
Inhibitory Effect: By irreversibly inhibiting ERBB tyrosine kinase activity, Dacomitinib inhibits cell growth and induces apoptosis. It has shown significant inhibitory effects on NSCLC in vitro and in vivo studies.